ClinicalTrials.gg
RecruitingNCT07603804AIM-DUpdated May 22, 2026

Accelerated iTBS for Major Depression

An interventional study of Accelerated Intermittent Theta Burst Stimulation (iTBS) in Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD), sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.

Planned enrollment
20th of 24
35 · median 95
Started
2026
with 6 others
No phase
11 of 32
6 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
24th of 32
by date
Lead sponsor
4 of 32
Istanbul University - Cerrahpasa

Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2026, is one of 11 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 24th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Depressive Disorder, Major with a site in Turkey, or all of them as a file.
02

Study summary

Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments. Accelerated intermittent theta burst stimulation (iTBS) is a promising neuromodulation approach that may provide rapid antidepressant effects. This prospective interventional study aims to evaluate the clinical effectiveness of accelerated bilateral dorsomedial prefrontal cortex iTBS in patients with MDD and to investigate treatment-related changes in neurobiological biomarkers, including cortisol, ACTH, BDNF, IL-1β, IL-6, TNF-α, and CRP. Associations between biomarker changes and treatment response will also be examined.

Read the detailed description

Major depressive disorder (MDD) is a highly prevalent and disabling psychiatric disorder. A substantial proportion of patients do not achieve sufficient improvement with conventional antidepressant treatments, resulting in treatment-resistant or difficult-to-treat depression. Noninvasive neuromodulation approaches such as transcranial magnetic stimulation (TMS) have emerged as effective alternatives for these patients. Accelerated intermittent theta burst stimulation (iTBS), delivered in multiple daily sessions over a short period, may provide faster clinical improvement compared with conventional protocols.

This prospective single-arm interventional study aims to evaluate the clinical efficacy and biological correlates of accelerated bilateral dorsomedial prefrontal cortex (DMPFC) iTBS in adults with MDD who have shown inadequate response to at least one adequate antidepressant treatment trial.

Participants aged 18 to 65 years will receive accelerated bilateral DMPFC iTBS for five consecutive days, with four sessions per day (20 total sessions). Participants demonstrating partial clinical improvement without remission after 20 sessions may receive an additional 10 sessions according to clinical evaluation.

Clinical assessments will be performed at baseline, during treatment, at the end of treatment, and at one-month follow-up. Outcome measures include Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory, Beck Anxiety Inventory, suicidal ideation measures, self-rated depressive symptom scales, and Clinical Global Impression ratings.

Blood samples will be collected at baseline and after treatment to evaluate neurobiological biomarkers, including cortisol, adrenocorticotropic hormone (ACTH), brain-derived neurotrophic factor (BDNF), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP).

The primary objective is to determine treatment response based on reduction in depressive symptom severity. Secondary objectives are to examine biomarker changes associated with treatment, identify predictors of response, and explore the relationship between early symptom improvement and final clinical outcomes.

03

Conditions studied

  • Major Depressive Disorder (MDD)
  • Treatment Resistant Depression (TRD)

Keywords

  • Major Depressive Disorder
  • Treatment Resistant Depression
  • Depression
  • Transcranial Magnetic Stimulation
  • TMS
  • Intermittent Theta Burst Stimulation
  • iTBS
  • Accelerated TMS
  • Accelerated iTBS
  • Dorsomedial Prefrontal Cortex
  • Biomarkers
  • Neuroinflammation
  • BDNF
  • Cortisol
  • ACTH
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Diagnosis of Major Depressive Disorder according to criteria
  • Inadequate response to at least one adequate antidepressant treatment trial
  • Hamilton Depression Rating Scale (HAM-D) score ≥14 at baseline
  • Stable dose of antidepressant medication for at least 4 weeks prior to study entry
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • History of bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic depression
  • Current substance use disorder
  • Neurological disorders that may affect brain function (e.g., epilepsy, multiple sclerosis, dementia, Parkinson's disease)
  • History of epileptic seizures
  • Severe head trauma
  • Presence of metal implants in the head or neck region
  • Cochlear implants
  • Cardiac pacemaker or implanted electronic devices
  • History of deep brain stimulation or vagus nerve stimulation
  • Previous neurosurgical procedures
  • Pregnancy or breastfeeding
  • Use of medications that may significantly affect neuroendocrine or inflammatory markers (e.g., , immunomodulators)
  • Endocrine disorders affecting the hypothalamic-pituitary-adrenal axis (e.g., Cushing's syndrome, Addison's disease, thyroid disorders)
  • diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, Hashimoto thyroiditis)
  • Recent surgery or acute infection
  • Active suicidal crisis, severe agitation, or inability to comply with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Accelerated iTBS

    Participants receive accelerated bilateral dorsomedial prefrontal cortex intermittent theta burst stimulation (iTBS) administered over five consecutive days, with four sessions per day (20 sessions total). Participants with partial clinical response may receive an additional 10 sessions.

    Device: Accelerated Intermittent Theta Burst Stimulation (iTBS)

Interventions

  • DeviceAccelerated Intermittent Theta Burst Stimulation (iTBS)

    Accelerated intermittent theta burst stimulation (iTBS) is administered bilaterally to the dorsomedial prefrontal cortex using a double-cone coil, targeting the stimulation site based on anatomical landmarks. Treatment is delivered over five consecutive days with four sessions per day (total of 20 sessions). Each session consists of 600 pulses per hemisphere (1200 pulses total) at an intensity of 120% of the individual motor threshold. Participants with partial response may receive an additional 10 sessions.

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HAM-D) Score

    Change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAM-D-17). Scores range from 0 to 53, with higher scores indicating greater depression severity.

    Time frame: Baseline, within 3 days after completion of treatment and 1-month follow-up

Secondary outcomes

  1. Treatment Response Rate Based on HAM-D

    Proportion of participants achieving ≥50% reduction in HAM-D score from baseline.

    Time frame: within 3 days after completion of treatment

  2. Remission Rate Based on HAM-D

    Proportion of participants achieving remission defined as HAM-D score ≤7.

    Time frame: Within 3 days after completion of treatment

  3. Sustained Treatment Response at 1-Month Follow-Up

    Proportion of participants maintaining ≥50% reduction in HAM-D score at 1-month follow-up.

    Time frame: 1 month after treatment completion

  4. Sustained Remission at 1-Month Follow-Up

    Proportion of participants maintaining remission, defined as HAM-D score ≤7, at 1-month follow-up.

    Time frame: 1 month after treatment completion

  5. Change in Serum Cortisol and ACTH Levels

    Change in serum cortisol and adrenocorticotropic hormone (ACTH) levels following treatment.

    Time frame: Baseline, within 3 days after completion of treatment and 1-month follow-up

  6. Change in Serum BDNF Levels

    Change in serum brain-derived neurotrophic factor (BDNF) levels following treatment.

    Time frame: Baseline, within 3 days after completion of treatment, and 1-month follow-up

  7. Change in Inflammatory Biomarkers

    Change in serum IL-1β, IL-6, TNF-α, and C-reactive protein (CRP) levels following treatment.

    Time frame: Baseline, within 3 days after completion of treatment, and 1-month follow-up

  8. Change in Beck Depression Inventory (BDI) Score

    Change in depressive symptom severity measured by the Beck Depression Inventory(BDI). Scores range from 0 to 63, with higher scores indicating greater depressive symptom severity.

    Time frame: Baseline, within 3 days after completion of treatment, and 1-month follow-up

  9. Change in Beck Anxiety Inventory (BAI) Score

    Change in anxiety symptom severity measured by the Beck Anxiety Inventory (BAI). Scores range from 0 to 63, with higher scores indicating greater anxiety severity.

    Time frame: Baseline, end of treatment, and 1-month follow-up

  10. Change in Clinical Global Impression (CGI) Score

    The scale includes three clinician-rated dimensions assessing illness severity (1-7), clinical improvement (1-7), and side effect severity (1-4).

    Time frame: Baseline, within 3 days after completion of treatment and 1-month follow-up

07

Study locations

1 of 1 sites recruiting
  • Istanbul University - Cerrahpasa
    Istanbul, 34000, Turkey (Türkiye)
    Recruiting
    • Merve rANA Altunel Ülkü, MD · Contactranaltunel@gmail.com · +90 506 303 10 68
    • Cana Aksoy Poyraz, Prof. Dr. · Contactaksoycana@gmail.com · +90 532 715 95 04
    • Merve Rana Altunel Ülkü, MD · Principal investigator
    • Cana Aksoy Poyraz, Prof. Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared due to institutional and ethical considerations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 9 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 22, 2026
StartActual
Mar 8, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 31, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07603804
Responsible party
Merve Rana Altunel (Principle Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
May 22, 2026
Start date
Mar 8, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Merve Rana Altunel Ülkü, MD
Contact
ranaltunel@gmail.com
+90 506 303 10 68
Cana Aksoy Poyraz, Prof. Dr.
study chair · Istanbul University - Cerrahpasa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion